Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study

Rutger Goekoop1, Serge A R B Rombouts, Cees Jonker

  • 1Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands. R.Goekoop@vumc.nl

Neuroimage
|December 14, 2004
PubMed

Insights

Functional magnetic resonance imaging (fMRI) detected changes in brain activation in mild cognitive impairment (MCI) patients after galantamine treatment. This suggests fMRI can reveal neurochemical system status in early Alzheimer disease (AD).

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medical Imaging

Background:

  • Mild cognitive impairment (MCI) is an early sign of Alzheimer disease (AD), often involving cholinergic system changes.
  • Functional magnetic resonance imaging (fMRI) can assess neurochemical alterations via pharmacological challenge.

Purpose of the Study:

  • To investigate brain activation changes in MCI patients using fMRI under different galantamine (GAL) dosages.
  • To examine the effects of GAL on memory task performance and associated neural activity.

Main Methods:

  • A randomized trial involving 28 MCI patients scanned using fMRI under three conditions: baseline, single-dose GAL, and steady-state GAL.
  • Memory tasks included episodic face encoding and an n-back working memory task.
  • Multilevel statistical analysis was used to compare brain activation patterns.

Main Results:

  • Prolonged GAL exposure significantly increased brain activation in MCI patients compared to baseline.
  • Specific areas showing increased activation included the prefrontal cortex, anterior cingulate, occipital cortex, and hippocampus for face encoding.
  • Working memory task performance and accuracy improved with GAL treatment, correlated with increased activation in the precuneus and middle frontal gyrus.

Conclusions:

  • Cholinergic challenge with GAL alters brain activation patterns in MCI patients, detectable by fMRI.
  • fMRI is a viable tool for studying neurotransmitter system status in early-stage neurodegenerative diseases like AD.
  • Further research using functional imaging is warranted to explore neurotransmitter systems in disease states.